Ola A Al-Ewaidat,Moawiah M Naffaa
Ola A Al-Ewaidat
Tumor heterogeneity and cellular plasticity are major drivers of therapeutic failure across many cancer types. While precision oncology has largely focused on static genomic alterations, growing evidence indicates that tumors behave as dyna...
L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer [0.03%]
DNA-PK抑制剂在胰腺癌中的敏感标志物L3MBTL4甲基化
Yuanxin Yao,Yuan Li,Aiai Gao et al.
Yuanxin Yao et al.
Aim: The purpose is to explore the mechanism and new therapeutic strategy of lethal 3 malignant brain tumor like 4 (L3MBTL4) gene in pancreatic ductal adenocarcinoma (PDAC). ...
Mechanistic study of antisense long non-coding RNA STEAP3-AS1 in breast cancer [0.03%]
反义长非编码RNA STEAP3-AS1在乳腺癌中的作用及机制研究
Jinquan Sun,Jiayong Cui,Tianlei Qiu et al.
Jinquan Sun et al.
Aim: This study aims to investigate the expression and function of antisense long non-coding RNA (lncRNA) STEAP3-AS1 in breast cancer (BC). Additionally, it explores STEAP3's regulatory relationship with STEAP3-AS1 and po...
Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities [0.03%]
活性氧（ROS）与癌症：从氧化还原信号传导和代谢重组到治疗弱点
Taslim Uddin,Tajmin Khanam,Afia Asma et al.
Taslim Uddin et al.
Reactive oxygen species (ROS) are important regulators of cancer biology, acting as tumor-promoting signaling mediators and inducers of oxidative cell death. Oncogenic signaling, mitochondrial dysfunction, metabolic rewiring, and microenvir...
Predictive biomarkers for immunotherapy response in endometrial cancer: current insights and future directions [0.03%]
子宫内膜癌免疫治疗反应的预测生物标志物：当前见解与未来方向
Giuliana Pavone,Alessandra Spata,Marialuisa Puglisi et al.
Giuliana Pavone et al.
In recent years, immunotherapy has modified the treatment landscape of advanced and recurrent endometrial cancer (a/rEC), particularly for patients with defective mismatch repair and microsatellite instability-high (dMMR/MSI-H), significant...
Impact of smoking on subtypes and molecular profile of breast cancer: a systematic review [0.03%]
吸烟对乳腺癌亚型和分子特征影响的系统评价研究进展
Georgia Ntella,Anastasia Bothou,Giannoula Kyrkou et al.
Georgia Ntella et al.
Background: Breast cancer encompasses heterogeneous pathological and molecular subtypes with distinct aetiologies and clinical outcomes. Although cigarette smoking is an established carcinogenic exposure, its subtype-spec...
Why precision oncology works: lessons from gastrointestinal stromal tumours [0.03%]
精准肿瘤学为何有效——胃肠道间质瘤的启示
Si Ying Adelina Ho,Alwyn Hong Sheng Tok,Hui Qi Megan Kimberly Han et al.
Si Ying Adelina Ho et al.
Gastrointestinal stromal tumours (GISTs) are the clearest solid-tumour model of precision oncology because diagnosis, prognosis, and treatment are strongly shaped by molecular genotype. The discovery of activating mutations in KIT proto-onc...
More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer [0.03%]
超越替代雌激素受体：GPER-1和ERα36在乳腺癌中的新角色
Luis Molina Calistro,Rodrigo Flavio Torres,Johana Spies et al.
Luis Molina Calistro et al.
Breast cancer classification and therapeutic decision-making have traditionally relied on the evaluation of estrogen receptor alpha (ERα), PR, and HER2, yet this framework does not fully explain tumor heterogeneity, endocrine resistance, o...
Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer [0.03%]
恩沃单抗联合派姆单抗一线治疗晚期尿路上皮癌的肿瘤学疗效和安全性：与标准化疗比较
Makito Miyake,Nobutaka Nishimura,Yuki Oda et al.
Makito Miyake et al.
Aim: The aim of this multicenter study was to assess patient characteristics and short-term survival outcomes of first-line (1L) enfortumab vedotin plus pembrolizumab (EVP) as compared with conventional chemotherapy in lo...
Afeez Adekunle Ishola,Nalini Devi Verusingam,Bashir Lawal
Afeez Adekunle Ishola
In 2013, more than a decade ago, the "Recalcitrant Cancer Research Act of 2012" was signed into law in the USA. Recalcitrant cancers are among the leading causes of global cancer morbidity and mortality. At the inception of the act, priorit...